Objectives: To assess the association between provider characteristics and intensity of endovenous therapy (EVT) use in the Medicare population.
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Impact of Provider Characteristics on Use of Endovenous Ablation Procedures in Medicare Beneficiaries
Methods: The Medicare Provider Utilization and Payment Data Public Utilization Files (2012 Files ( -2014 were queried to construct a database of providers performing EVT for treatment of lower extremity venous reflux. For all providers performing EVT on more than 10 patients annually, practice patterns were assessed by calculating a use index: the number of EVT procedures per patient per year. To measure geographic variation in EVT use at the provider level, the median number of EVT performed annually per provider per year was calculated. Multivariate regression analysis was used to identify provider characteristics (including specialty, site of service, and geography) associated with high intensity use of EVT (a use index >75th percentile).
Results: There were 6599 providers who performed more than 10 EVT per year in Medicare beneficiaries, accounting for 405,232 services. The intensity of EVT use by providers was assessed by the calculated use index: the average number of EVT performed per patient per year (range, 1-4). Vascular surgeons had the lowest use index among all provider specialties (1.32; Fig 2) . By multivariate analysis, the likelihood of a providers use index being greater than 1.8 (top 25%) was associated with provider training in a field other than surgery, cardiology, or radiology (odds ratio, 3.35; 95% confidence interval, 2.74-4.09), services performed in an outpatient setting (odds ratio, 2.62; 95% confidence interval, 1.97-3.47), and providers who perform high annual volume of EVT (odds ratio, 8.68; 95% confidence interval, 7.59-9.91). A high annual volume provider was defined as one whose EVT volume was at or greater than the 75th percentile nationally.
Conclusions: There is great variation in intensity of vein ablation procedures performed on Medicare beneficiaries that cannot readily be explained by clinical factors alone. The likelihood that a provider will perform multiple EVT on a patient within a given calendar year is predictable based on the provider's geographic location, site of service (facility vs hospital), specialty, and annual EVT volume. Of particular concern is the high intensity of EVT use by providers with specialty certification not typically associated with the management of venous disease.
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Safety and Performance of the Veniti VICI Venous Stent in Patients With Venous Outflow Obstructions: Results From the Arnsberg Venous Registry
Michael K. W. Lichtenberg. Arnsberg Clinic, Arnsberg, Germany
Objectives: To determine patency of the Veniti VICI venous stent device for the treatment of venous obstruction of the lower extremities.
Methods: From 2014 to 2016, patients undergoing a Veniti VICI venous stent implantation for venous outflow obstruction were analyzed for patency and clinical symptom resolution. Patient charts from this prospectively maintained registry were reviewed for patient demographics, patency and reinterventions, clinical, etiology, anatomy, and pathophysiology, and the revised Venous Clinical Severity score.
Results: A total of 90 consecutive patients (57% female; mean age, 57.4 years) were treated successfully during the aforementioned timeframe. The 12-month patency was 92.2%, 92.2%, and 93.9% for primary, assisted primary, and secondary patency, respectively. Five patients presented with stent reocclusion during the 12-month follow-up period and three of them underwent reintervention. Clinical improvement with a gain of two or more revised Venous Clinical Severity score levels was observed in 82%, 90%, and 76% of patients at 1, 6, and 12 months, respectively. Primary patency differed significantly between nonthrombotic iliac vein lesion and postthrombotic lesions. All nonthrombotic iliac vein lesions remained patent throughout 12 months, whereas postthrombotic lesions were associated with a 12-month primary patency rate of 85.7%.
Conclusions: The Veniti VICI venous stent holds promise as a treatment modality for chronic venous occlusion with good short-term patency and quality-of-life outcome. Long-term studies are needed to evaluate the durability of the procedure. Background: In this video, we present a complex removal of an inferior vena cava (IVC) filter and a caval leiomyoma. The patient is a 51-year-old 
